BioRestorative Therapies (BRTX) Enterprise Value (2016 - 2025)
BioRestorative Therapies (BRTX) has disclosed Enterprise Value for 14 consecutive years, with -$7.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 40.6% year-over-year to -$7.8 million, compared with a TTM value of -$7.8 million through Sep 2025, up 40.6%, and an annual FY2024 reading of -$10.7 million, up 3.01% over the prior year.
- Enterprise Value was -$7.8 million for Q3 2025 at BioRestorative Therapies, up from -$11.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.1 million in Q3 2021 and bottomed at -$30.5 million in Q1 2024.
- Average Enterprise Value over 5 years is -$14.1 million, with a median of -$13.9 million recorded in 2024.
- The sharpest move saw Enterprise Value crashed 52220.27% in 2021, then skyrocketed 70.14% in 2025.
- Year by year, Enterprise Value stood at -$21.0 million in 2021, then grew by 29.85% to -$14.7 million in 2022, then grew by 24.97% to -$11.1 million in 2023, then grew by 3.01% to -$10.7 million in 2024, then grew by 27.56% to -$7.8 million in 2025.
- Business Quant data shows Enterprise Value for BRTX at -$7.8 million in Q3 2025, -$11.7 million in Q2 2025, and -$9.1 million in Q1 2025.